Underreporting of Patient Reported Outcomes (PRO) in Myeloproliferative Neoplasms (MPNs) Clinical Trials

Patient-reported outcomes provide unique and meaningful insight about the effect of a treatment from a patient’s view. Patients with MPNs today can live with their disease for long periods of time. Therefore a comprehensive evaluation of treatment effectiveness should consider the patient burden of the disease and treatment effect. 

View the Poster